期刊
EPMA JOURNAL
卷 11, 期 4, 页码 603-627出版社
SPRINGER INT PUBL AG
DOI: 10.1007/s13167-020-00226-x
关键词
Predictive preventive personalised medicine (PPPM; 3PM); Cell-free nucleic acids (CFNAs); miRNA; Biomarker panel; Methylation status; Physical activity; Apoptosis; Systemic hypoxic-ischemic lesion; Tumour development progression; Cancer; Stroke; cfDNA; ctDNA; Diet; Blood; Plasma; Serum; Saliva; Stress; Associated disease; Cardiovascular; Neurologic; Virus; COVID-19; Liquid biopsy; Therapy monitoring; Qualitative and quantitative analysis; Precancerous lesions; Mutations; Breast cancer; Colorectal cancer; Lung cancer; Prostate cancer; Diabetes; Metabolic disorder
资金
- Projekt DEAL
Interest in the use of cell-free nucleic acids (CFNAs) as clinical non-invasive biomarker panels for prediction and prevention of multiple diseases has greatly increased over the last decade. Indeed, circulating CFNAs are attributable to many physiological and pathological processes such as imbalanced stress conditions, physical activities, extensive apoptosis of different origin, systemic hypoxic-ischemic events and tumour progression, amongst others. This article highlights the involvement of circulating CFNAs in local and systemic processes dealing with the question, whether specific patterns of CFNAs in blood, their detection, quantity and quality (such as their methylation status) might be instrumental to predict a disease development/progression and could be further utilised for accompanying diagnostics, targeted prevention, creation of individualised therapy algorithms, therapy monitoring and prognosis. Presented considerations conform with principles of 3P medicine and serve for improving individual outcomes and cost efficacy of medical services provided to the population.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据